Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
Medicines regulator Health Canada has approved Orgovyx (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer, Japanese drugmaker Sumitomo Pharma announced. 24 October 2023
Pharmaceutical
Seven vaccine research proposals have been chosen for funding, the latest development in a partnership between the Bill and Melinda Gates Foundation and the National Natural Science Foundation of China (NSFC). 24 October 2023
Pharmaceutical
Novartis has lifted its 2023 earnings forecast for the third time. 24 October 2023
Pharmaceutical
In October 2022, the US Food and Drug Administration (FDA) released its “Multiple Endpoints in Clinical Trials” document to provide guidance for drug sponsors and other stakeholders regarding best practices in assessment methodologies for medications. 24 October 2023
Pharmaceutical
A new pill for dengue fever developed by US healthcare giant Johnson & Johnson appeared to protect against a form of the virus in a handful of patients in a small human challenge trial in the USA, according to data presented by the company on Friday. 23 October 2023
Pharmaceutical
US pharma major Eli Lilly released five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer. 23 October 2023
Pharmaceutical
The US Food and Drug Administration (FDA) on Friday approved Penbraya (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the five most common serogroups causing meningococcal disease in adolescents and young adults aged 10 through 25 years. 23 October 2023
Pharmaceutical
Melbourne, Australia-based Dimerix has appointed Dr David Fuller as chief medical officer (CMO), effective immediately. 23 October 2023
Pharmaceutical
The global pharmaceutical industry is going through a significant shift in the way it operates. Dr Stefanie Lietsch-Dallwig shares her insights on how this shift will impact the local affiliate model in an Expert View piece. 20 October 2023
Pharmaceutical
Californian antiviral specialist Gilead Sciences has presented new data today supporting Sunlenca (lenacapavir) as an important treatment option for adults with multi-drug resistant (MDR) HIV who have extensive treatment history. 20 October 2023
Pharmaceutical
US pharma giant Pfizer has revealed the cost of its oral antiviral treatment for COVID-19, Paxlovid (nirmatrelvir/ritonavir), once the company starts selling the drug commercially. 20 October 2023
Pharmaceutical
New Jersey, USA-based PTC Therapeutics has announced an agreement with Royalty Pharma to acquire additional royalties on Evrysdi (risdiplam) for $1 billion upfront. 20 October 2023
Pharmaceutical
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with privately owned US firm Gravitas Therapeutics for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species. 20 October 2023
Pharmaceutical
In September, USA-based Ionis Pharmaceuticals (Nasdaq: IONS) unveiled positive Phase III clinical data for olezarsen, a ligand-conjugated antisense (LICA) designed to inhibit apolipoprotein C-III (apoC-III). 20 October 2023
Pharmaceutical
Nearly five months have passed since the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place, and cancer-focused drugmakers are ready once again to dump their data to the world’s oncologists, media and more. 19 October 2023
Pharmaceutical
US biotech major Gilead Sciences has presented new long-term real-world data on its flagship medication Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF). 19 October 2023
Pharmaceutical
The GSK majority-owned company ViiV Healthcare is presenting 12-month efficacy, safety and patient-reported outcomes for European participants in the SOLAR study at the Annual European AIDS Conference (EACS) 2023 in Warsaw, Poland. 19 October 2023
Pharmaceutical
German active pharmaceutical ingredient (API) manufacturer Axplora has appointed Stephan Haitz as president of the Novasep business unit. 19 October 2023
Pharmaceutical
Swiss pharma giant Roche saw its shares fall more than 5% to 254.60 francs this morning, after it posted a cautious forecast for full-year 2023. 19 October 2023
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late yesterday confirmed that pre-filled pens falsely labeled as the diabetes medicine Ozempic (semaglutide, 1mg, solution for injection) have been identified at two UK wholesalers. 19 October 2023
All news
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze